Kaleido Biosciences Reports Third Quarter 2021 Financial Results

--Achieved primary objective of safety and tolerability in clinical study evaluating KB295 in mild-to-moderate ulcerative colitis; meaningful reduction observed in key biomarkers correlated with disease activity and inflammation--

Read more at globenewswire.com